



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 27th March 2023

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Teams. The minutes and summary notes of the Medicines Group Meeting held on 30th January 2023 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Ultibro Breezhaler - 85micrograms/43micrograms Inhalation Powder capsules with device (Glycopyrronium Bromide 54microgram per dose and Indacaterol (as Indacaterol Maleate) 85microgram per dose)**

Requested by: Respiratory

Indication: Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD)

Proposal: Add to the formulary

Rational: To be used in line with NICE Guidance and NWL COPD management guidelines - To increase inhaler choice as per North West London Formulary. Patients will also be admitted with these inhalers as it is now on the North West London COPD Inhaler Guideline

Cost: £32.50 per month

Notes: Likely to treat 50-100 patients at each hospital site per year.

Included on the NWL Integrated Formulary for requested indication.

Outcome: Approved for addition to the Trust Formulary

- **Duaklir Genuair 340microgrammes/12microgrammes inhaler (Aclidinium 340micrograms per dose and Formoterol 12micrograms per dose)**

Requested by: Respiratory

Indication: Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD)

Proposal: Add to the formulary

Rational: To be used in line with NICE Guidance and NWL COPD management guidelines - To increase inhaler choice as per North West London Formulary. Patients will also be admitted with these inhalers as it is now on the North West London COPD Inhaler Guideline

Cost: £32.50 per month

Notes: Likely to treat 25-50 patients at each hospital site per year.

Included on the NWL Integrated Formulary for requested indication.

Outcome: Approved for addition to the Trust Formulary

- **Spiolto Respimat Inhalation Solution (Tiotropium 2.5micrograms per dose and Olodaterol 2.5microgram per dose)**

Requested by: Respiratory

Indication: Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD)

Proposal: Add to the formulary



Rational: To be used in line with NICE Guidance and NWL COPD management guidelines - To increase inhaler choice as per North West London Formulary. Patients will also be admitted with these inhalers as it is now on the North West London COPD Inhaler Guideline

Cost: £32.50 per month

Notes: Likely to treat 50-100 patients at each hospital site per year.

Included on the NWL Integrated Formulary for requested indication.

Outcome: Approved for addition to the Trust Formulary

Ex-panel

• **Nicotine 1mg/dose Mouthspray (Nicorette Quickmist®)**

Requested by: Respiratory

Indication: Management of Nicotine withdrawal symptoms in nicotine dependence who are currently vaping.

Proposal: Add to the formulary for the management of patient requiring replacement during their in-patient stay. Pharmacists will be providing smoking cessation advice to in-patients and making referrals to their local smoking cessation services in the community who will continue prescribing nicotine replacement for 6 weeks or until the patient has a quit date.

Rational: Additional option for patients wanting to quit vaping.

Cost: 1 x 13.2ml £14.24 and 26.4ml £22.53

Likely to treat 200 patients per year at each hospital site.

Included on the NWL Integrated Formulary for requested indication.

Outcome: Deferred to May 2023

• **Colecalciferol 25,000 unit/ml Oral Solution (InVita D3)**

Requested by: Paediatric Endocrinology

Indication: Management of Vitamin D Deficiency

Proposal: Add to the formulary as a liquid option used in line with Trust Vitamin D Guidelines.

Rational: To replace the existing 2 liquid preparations currently included on the formulary as 1st line as these are more expensive and usually subject to supply issues. To maintain all three liquid formulations on the formulary as the two existing formulations continue to be required for administration via feeding tubes.

Cost: £3.58 per pack of 3 ampoules

Product	Cost for a 30,000unit dose
3,000unit/ml Oral Solution	£136.00
2,740unit/ml Oral Solution	£104.00
25,000unit/ml Oral Solution	£4.30

Notes: Likely to treat 200 patients (CWH) and 100 patients (WMUH) per year.

Included on the NWL Integrated Formulary for requested indication.

Outcome: Approved for addition to the Trust Formulary

• **Memantine 20mg Tablets**

Requested by: Neurology

Proposal: Add 20mg tablets to the formulary to provide more flexibility with dosing.

Memantine 10mg tablets are already on the formulary.

Outcome: Approved for addition to the Trust Formulary

• **Tiopex (Preservative-Free) Eye Gel (Timolol 1mg/g)**

Requested by: Ophthalmology

Indication: Management of Glaucoma

Proposal: Add to the formulary

Rational: Provision or additional flexibility to suit patients' needs (No preservative-free once daily dosing formulation available on the formulary. Also this is a gel formulation which may be a more preferred formulation than the drops for some patients)

Patients are currently using Timolol 05% Eye Drops

Likely usage: 50 patients at CWH Site per year



Cost: Cost pressure of £286 if switching from Timolol 0.5% Eye Drops.
Included on the Pan London Ophthalmology Formulary
Included on the NWL Integrated Formulary

Outcome: Approved for addition to the Trust Formulary

- **Fixapost (Preservative-Free) Eye Drops (Timolol 5mg/Latanoprost 50mcg/ml)**

Requested by: Ophthalmology

Indication: Management of Glaucoma

Proposal: Add to the formulary

Rational: Provision or additional flexibility to suit patients' needs (No preservative-free combination preparation available on the formulary.

Patients are currently using separate Preservative Free drops.

Likely usage: 50 patients at CWH Site per year

Cost: Fixapost Drops are £4.41* cheaper per month compared to using the separate Preservative-Free drops therefore a cost saving of £220 per year.

Included on the Pan London Ophthalmology Formulary

Included on the NWL Integrated Formulary

Outcome: Approved for addition to the Trust Formulary

Removals

- Nil

NICE Approved drug applications

- **TA856 - Upadacitinib for treating moderately to severely active Ulcerative Colitis**

Approved by Chair's Action on 06/01/2023

Outcome: Approved for addition to the Trust Formulary for use in line with TA856

- **TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over** Proposal: Add to the formulary in line with NICE TA863

Outcome: Approved for addition to the Trust Formulary for use in line with TA863

- **TA871 - Eptinezumab for preventing Migraine**

Proposal: Add to the formulary in line with NICE TA871

Outcome: Approved for addition to the Trust Formulary for use in line with NICE TA871

Pharmacoeconomic Board requests

- **Ustekinumab for Crohn's Disease**

Approved by the Pharmacoeconomic Board on 14/02/2023

Outcome: Noted

- **Infliximab for Pyoderma Gangrenosum**

Approved by the Pharmacoeconomic Board on 02/03/2023

Outcome: Noted

Other

- **EAS - Upadacitinib for Crohn's Disease**

EAM involving the treatment of Crohn's Disease with oral Upadacitinib (15mg, 30mg and 45mg Tablets)

Unmet clinical need as this is the first oral Biologic available for the management of Crohn's Disease.

Outcome: Scheme is approved for use in the Trust

4.2 Trust Medicines Policy

- **TMP Section 31 - Medicine Management Training**

Routine review and update



- Full review and update of content
- Training descriptions merged into a separate cross-site section where training is delivered across both hospital sites
- Reviewed and updated in collaboration with training leads
- Staff names replaced with role titles

Outcome: Approved

- **TMP Section 11 - Medicines Recalls**

Reviewed in line with Pharmacy Recall procedure

Outcome: Approved

4.3 Medicines Optimisation

- **Trust Medicines Optimisation Annual Report 2021-2022**

Medicines optimisation encompasses a range of activities intended to improve the way that medicines are selected, procured, prescribed, dispensed and administered.

This report summarises the activities of groups responsible for the management of medicines at Chelsea and Westminster Hospital NHS Foundation Trust, describes developments throughout the 2021-22 year and reports on results of external assessments.

Summary

- Trust Medicines Group meeting x 5 held
- Formulary applications: 45 x applications - 12 x full submissions, 15 x ex-panel requests and 18 x Individual Funding Requests (approved by Pharmacoeconomic Board)
- Trust Medicines Policy: 18 x updates approved
- NICE Technology Appraisals: 93 x NICE TAs noted and actioned; 4 HSTs noted
- Patient Group Directions: 7 x PGDs approved - 4 x existing PGDs and 3 x newly drafted
- IV Immunoglobulin: 128 x issues for immunoglobulin for new patients approved across both sites
- Chemotherapy: £180k drug savings (Pemetrexed switch to generic)
- Antimicrobial Stewardship: CQUINs were suspended due to Covid-19 Pandemic but historic targets optimised (Reducing total antibacterial usage across the Trust; Reducing quinolones and carbapenem usage; Reducing C Difficile Infections, Optimising antifungal usage) 6 x Guidelines updated; 9 x Audits undertaken
- VTE Prevention: The Trust did not achieve the national target of $\geq 95\%$ (Achieved: 93.18%) for VTE risk assessment completion for adult patients on admission to hospital in 2021-22. Increased optimisation of electronic VTE risk assessment with Cerner functionality; 3 x Guidelines updated; 1 x Audits undertaken
- Homecare: As at March 2022, 3,786 patients enrolled and receiving medicines via Homecare services.
- Medication Safety: A total of 1,405 medicine-related incidents reported across the Trust representing a 8.5% increase in incident reporting across both hospital sites. 3 x NHS England Alerts actioned; 7 x MSG meetings held; 11 x Medication Safety Bulletins published;
- Controlled Drugs: 59 incidents of unaccounted for CDs of which 7 x incidents reports to NHS England
- Non-Medical Prescribers: 83 x NMPs in post and on the Trust NMP Register
- EPMA: Paperless outpatient prescribing went live in out-patient areas in October 2021. Powertrials Clinical Trials Module went live in November 2021.
- Clinical Trials: 75 x active Clinical Trials (60 at CWH and 15 at WMUH)
- Medicines related cost savings: £220k In-tariff
- Medicines Policy was audited
- Medicines Information: 891 x enquiries received and managed (752 from HCPs and 139 from members of the public)
- Research: Pharmacy staff involved in 20 x publications

This report will be sent to Patient Safety Group for noting.

Outcome: Approved

4.4 NICE Technical Appraisals and Guidance

21 TA appraisals published between end January to early March 2023



TA855 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (04/01/2023)

Formulary status / Action

Included on the formulary for another indication

Action: Approve for addition to the formulary following receipt of an application form from the Oncology Team

TA856 Upadacitinib for treating moderately to severely active Ulcerative Colitis (04/01/2023)

Formulary status / Action

Action: Included on formulary for treatment of RA (NICE TA 665)

Application form included in Section 4.1

TA857 Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (11/01/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat:

CWH: 1 patient per year

WMUH: 0 patients per year

TA858 Lenvatinib with Pembrolizumab for untreated advanced renal cell carcinoma (11/01/2023)

Formulary status / Action

Both included on the formulary for this indication

Numbers likely to treat in combination:

CWH: Patients likely to be treated per year to be confirmed

WMUH: 0 patients per year

TA859 Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock (Terminated appraisal) (16/01/2023)

Formulary status / Action

Nil - Terminated Appraisal

TA860 Maribavir for treating refractory cytomegalovirus infection after transplant (18/01/2023)

Formulary status / Action

Action: Nil - Not relevant to CWFT

TA861 Upadacitinib for treating active non-radiographic axial spondyloarthritis (01/02/2023)

Formulary status / Action

Included on the formulary for RA

Numbers likely to treat:

CWH: 5 patients per year

WMUH: 20 patients per year

TA862 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (01/02/2023)

Formulary status / Action

Included on the formulary for this indication

Numbers currently treat:

CWH: 0 patients per year

WMUH: Patients likely to be treated per year to be confirmed

TA863 Somatrogen for treating growth disturbance in children and young people aged 3 years and over (01/02/2023)

Formulary status / Action

Not included on the formulary for this indication

Add to the formulary following receipt of an application form from Paediatrics

Application form included in Section 4.1 for approval



TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (01/0/2023)

Formulary status / Action

Included on the formulary for another indication

Action: Nil as CWFT is not a commissioned site

TA865 Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (08/02/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers currently treat:

CWH: 1 patient per year

WMUH: 0 patients per year

TA866 Regorafenib for previously treated metastatic colorectal cancer (08/02/2023)

Formulary status / Action

Nil - Application submitted and approved at TMG January 2023

TA867 Mitapivat for treating pyruvate kinase deficiency (15/02/2023)

Formulary status / Action

Nil - Terminated Appraisal

TA868 Vutrisiran for treating hereditary transthyretin-related amyloidosis (15/02/2023)

Formulary status / Action

Not included on the formulary

Action: Nil - Not treated by CWFT (Relevant patients would be referred to the Royal Free Hospital)

TA869 Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (16/02/2023)

Formulary status / Action

Nil - Terminated Appraisal

TA870 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (22/02/2023)

Formulary status / Action

Both included on the formulary to treat this indication

Numbers currently treat:

CWH: Patients likely to be treated per year to be confirmed

WMUH: Patients likely to be treated per year to be confirmed

TA871 Eptinezumab for preventing migraine (01/03/2023)

Formulary status / Action

Not included on the formulary

Action: Add to the formulary following receipt of an application form from the Neurology Department

Application form included in Section 4.1 for review

TA872 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (28/02/2023)

Formulary status / Action

Not included on the formulary

Formulary status / Action

Action: Nil as CWFT is not a commissioned site

TA873 Cannabidiol for treating seizures caused by tuberous sclerosis complex (01/03/2023)

Formulary status / Action

Not included on the formulary

Action: Nil - Not applicable to CWFT as patients are not treated with this condition at CWFT (Patients would be referred to GOSH).

TA874 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (01/03/2023)



Formulary status / Action

Not included on the formulary

Action: Add to the formulary following receipt of an application form from the Oncology Department

TA875 Semaglutide for managing overweight and obesity (08/03/2023)

Formulary status / Action

Wegovy brand not included on the formulary

Action: Add to the formulary following receipt of an application form from the Endocrine Department

b) NICE Highly Specialised Technology Appraisals published since last meeting

2 HST appraisal published between end January to early March 2023

HST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene

Action: Nil - Not applicable to CWFT

HST23 Asfotase alfa for treating paediatric-onset hypophosphatasia

Action: Nil - Not applicable to CWFT

4.5 IVIG requests

• IVIG Issues for December 2022 - CW Site

There were 17 IVIG issues in December 2022, with 10 new requests

Outcome: Noted

• IVIG Issues for December 2022 - WMUH Site

There were 9 IVIG issues in December 2022, with 3 new requests

Outcome: Noted

• IVIG issues for January 2023 - CWH Site

There were 15 IVIG issues in January 2023, with 9 new requests

Outcome: Noted

• IVIG issues for January 2023 - WMH Site

There were 12 IVIG issues in January 2023, with 7 new requests:

Outcome: Noted

The SRIAP did not approve the IVIG treatment for 1 patient with toxic epidermal necrolysis therefore IVIG was not issued to the patient.

4.6 Items for noting

• Quarterly Controlled Drug Summary Report - Q3 2022/23

Quarterly Controlled Drug Summary Report for Q3 2022/23

Outcome: Noted

• Quarterly Controlled Drugs Accountable Officer Report - Q3 2022/23

Quarterly CD Accountable Officer Report for Q3 2022/23

Outcome: Noted

• Medication Safety Bulletin: LASA Medications

Medication Safety Bulletin relating to LASA Medications

Outcome: Noted

• Medication Safety Bulletin: Summary of 2022 Incidents

Medication Safety Bulletin relating to Summary of 2022 Incidents



Outcome: Noted

- **MHRA Drug Safety Update - February 2023**

MHRA update for February 2023

Outcome: Noted

4.7 Meeting minutes for noting

- **Antimicrobial Stewardship Group meeting minutes - January 2023**

Minutes from Antimicrobial Stewardship Group meeting held January 2023

Outcome: Noted

5. Any other business

Nil

6. Date of next meeting

Next meeting

Date

May 15th 2023

Time: 8am-9am

Location: via Teams